Ekso Bionics (NASDAQ:EKSO) Stock Passes Above 50-Day Moving Average – What’s Next?

Shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) crossed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $10.54 and traded as high as $12.09. Ekso Bionics shares last traded at $11.38, with a volume of 44,443 shares traded.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Ekso Bionics in a research note on Friday, March 27th. HC Wainwright downgraded Ekso Bionics from a “buy” rating to a “neutral” rating in a research note on Wednesday, December 31st. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Reduce” and an average price target of $6.00.

Ekso Bionics Trading Up 1.5%

The company has a debt-to-equity ratio of 0.09, a quick ratio of 1.07 and a current ratio of 1.63. The company has a 50 day simple moving average of $10.60 and a two-hundred day simple moving average of $7.78. The firm has a market cap of $39.12 million, a PE ratio of -2.14 and a beta of 0.77.

Insiders Place Their Bets

In other news, major shareholder Daniel Asher purchased 15,540 shares of the company’s stock in a transaction on Thursday, February 19th. The shares were acquired at an average price of $12.30 per share, for a total transaction of $191,142.00. Following the purchase, the insider owned 270,432 shares in the company, valued at $3,326,313.60. This trade represents a 6.10% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On Ekso Bionics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Roble Belko & Company Inc lifted its holdings in shares of Ekso Bionics by 104.5% in the 1st quarter. Roble Belko & Company Inc now owns 2,338 shares of the company’s stock valued at $25,000 after buying an additional 1,195 shares during the period. Geode Capital Management LLC raised its holdings in Ekso Bionics by 68.9% in the 4th quarter. Geode Capital Management LLC now owns 25,212 shares of the company’s stock worth $218,000 after purchasing an additional 10,281 shares during the period. Citadel Advisors LLC acquired a new position in Ekso Bionics in the 3rd quarter worth about $198,000. Virtu Financial LLC acquired a new position in Ekso Bionics in the 3rd quarter worth about $57,000. Finally, Shay Capital LLC acquired a new position in Ekso Bionics in the 3rd quarter worth about $67,000. Institutional investors and hedge funds own 6.42% of the company’s stock.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.